CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 6375559
• 负责人: STEPHEN R SEAGREN
• 金额: $ 12.02万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-06 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6375559
• 关键词: AIDS related neoplasm /cancer; aging; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; carmustine; chemoprevention; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; finasteride; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human genetic material tag; human subject; human therapy evaluation; interleukin 2; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; oncology nursing; paclitaxel; pathology; prostate neoplasms; psychology; quality of life; respiratory neoplasm; tamoxifen; tissue resource /registry; weight loss

DESCRIPTION (adapted from the applicant's abstract): This application seeks support for the activities of CALGB investigators, participating through the University of California San Diego School of Medicine and adjunct institutions, in the programs of the Cancer and Leukemia Group B. Over the past grant cycle, significant contributions to the Group were made by our UCSD consortium. Investigators committed to CALGB have moved on to other member institutions. New UCSD faculty members are bringing fresh perspectives to the participation in clinical trials. Many changes in the health care system in Southern California have occurred impacting on the conduct of cooperative group studies. During the coming grant period, we will continue to make contributions to group accrual, group science, and group administration. We project stable to somewhat increased accrual over the 5 year upcoming grant cycle based on enhanced activities both at the main member institution and in our adjuncts, with a minimum goal of 125 accrued cases in the first year of this application. We expect women to be approximately 50 percent of all patients we accrue to clinical trials. Increased emphasis, will be placed on accruing minorities to CALGB studies. We expect to continue to contribute extensively to the intellectual productivity of the Group by designing and chairing protocols, presenting pilot observations for Group validation and expansion, and by stimulating more basic research components to Group activities. We plan to continue direct service to the group by providing a reference laboratory for new CALGB correlative science projects in breast cancer. Members of our institution expect to continue their major contributions to Group science/administration as committee chairs (Seagren - Radiation Oncology Modality Committee), Core Committee members, or members of standing Group scientific and administrative committees. We will continue to serve as a clinical resource and research base for CCOP activities of our CCOP adjunct in Las Vegas, Nevada, and at Kaiser CCOP San Diego and are working to further strengthen our clinical trials Outreach Network as a means to both assure accrual and stimulate and strengthen the intellectual vitality, and state-of-the-art quality of overall oncology care delivered in the entire San Diego area. Ongoing participation in CALGB continues to serve as an important educational vehicle for Faculty, Fellows, and House staff at UCSD, the Veterans Administration Medical Center, the Naval Medical Center, San Diego, Sharp Healthcare/Sidney Kimmell Cancer Center and Scripps Clinic and Research Foundation as well as for all the affiliated participants in private practice of hematology and medical oncology who share in our CALGB activities.

描述（改编自申请人的摘要）：本申请寻求 支持 CALGB 调查员的活动，通过参与 加州大学圣地亚哥分校医学院及其附属机构 机构，在癌症和白血病 B 组的计划中。 在过去的拨款周期中，我们的团队为集团做出了重大贡献 加州大学圣地亚哥分校联盟。 致力于 CALGB 的调查人员已转向其他领域 成员机构。 加州大学圣地亚哥分校的新教职员工带来了新鲜感 对参与临床试验的看法。 许多变化 南加州的医疗保健系统已经发生了影响 进行合作小组研究。 在接下来的资助期内，我们 将继续为团体应计、团体科学和 集团管理。 我们预计应计费用将稳定增长 即将到来的 5 年赠款周期基于增强的活动 主要成员机构和我们的附属机构，最低目标为 125 本申请第一年累积的案件数。 我们期望女性成为 我们招募的所有患者中约有 50% 接受了临床试验。 将更加重视吸引少数群体参与 CALGB 研究。 我们期望继续为知识分子做出广泛贡献 通过设计和主持协议来提高集团的生产力， 集团验证和扩展的试点观察，并通过刺激 集团活动中包含更多基础研究内容。 我们计划继续 通过为新产品提供参考实验室来直接为集团提供服务 CALGB 乳腺癌相关科学项目。 我们的成员 机构期望继续为集团做出重大贡献 科学/行政委员会主席（Seagren - 放射肿瘤学 模式委员会）、核心委员会成员或常设小组成员 科学和行政委员会。 我们将继续作为 我们的 CCOP 辅助人员的 CCOP 活动的临床资源和研究基地 内华达州拉斯维加斯和圣地亚哥 Kaiser CCOP 正在努力 进一步加强我们的临床试验外展网络作为实现这两个目标的手段 确保增长并激发和增强智力活力，以及 整个肿瘤学护理的最先进的质量 圣地亚哥地区。 持续参与 CALGB 继续作为 加州大学圣地亚哥分校的教职人员、研究员和学院工作人员的重要教育工具， 退伍军人管理局医疗中心、海军医疗中心、圣 迭戈、夏普医疗保健/悉尼金梅尔癌症中心和斯克里普斯诊所以及 研究基金会以及所有附属参与者 共享我们 CALGB 的血液学和肿瘤内科私人诊所 活动。